Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Transcatheter aortic valve replacement (TAVR) is safe in patients with severe aortic stenosis (AS) at intermediate surgical risk, with similar rates of mortality and disabling stroke at 2 y as surgical aortic valve replacement (SAVR).
TAVR patients had more major bleeding, major vascular complications, and permanent pacemaker (PPM) implantation and SAVR patients had more acute kidney injury (AKI) and atrial fibrillation (Afib).
Why this matters
Although TAVR has been studied extensively in high-risk patients, randomized studies of intermediate-risk patients were lacking.